Ensign Peak Advisors, Inc Aerovate Therapeutics, Inc. Transaction History

Ensign Peak Advisors, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$17.68 - $29.57 $2.48 Million - $4.14 Million	140,000 Added 114.51%	262,257 $7.75 Million
Q4 2023 Feb 14, 2024	BUY	$9.58 - $24.25 $1.03 Million - $2.6 Million	107,257 Added 715.05%	122,257 $2.77 Million
Q1 2023 May 15, 2023	SELL	$19.17 - $27.7 $119,007 - $171,961	-6,208 Reduced 29.27%	15,000 $302,000
Q4 2022 Feb 13, 2023	BUY	$15.92 - $30.52 $337,631 - $647,268	21,208 New	21,208 $621,000

28.4M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $63.1M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.